Aurobindo Pharma 

Aurobindo Pharma Limited is a Hyderabad-headquartered manufacturer of generic finished doses, active pharmaceutical ingredients and injectables, present in more than 150 countries. Founders P.V. Ramprasad Reddy and K. Nityananda Reddy incorporated the company in 1986. Commercial operations began in 1988–89 with a semi-synthetic penicillin facility at Pondicherry. The firm went public in 1992 and listed in 1995. The public line is Committed to Healthier Life: make medicines affordable and get them onto shelves that other supply chains miss. That is an industrial brief, not a diagnosis. Nothing here is medical advice. A licensed label and a treating physician decide what any patient uses. The portfolio has grown far beyond SSP. Biosimilars, dermatology, respiratory, injectables, vaccines, peptides, oncology and hormones sit beside a large oral-solids and API engine. Management talks about the group through operating clusters: APUSA for the United States, Europe, Growth Markets, the ARV franchise, Apitoria for APIs, Eugia for injectables and related work, and Curateq for biologics. Nine R&D centres—five in India, four in the United States—house more than 1,500 scientists. More than 29 plants carry USFDA, MHRA and other major-agency inspections. The company cites formulation capacity above 50 billion units and API capacity above 19,000 metric tonnes, plus a deep US ANDA stack with hundreds of filings and approvals. Those figures are Aurobindo’s; they live in annual reports, not in a social caption. Registered office remains Plot 2, Maitrivihar, Ameerpet; the corporate campus is Galaxy at Hyderabad Knowledge City, Raidurg. Vertical integration—from API tonnes to finished packs—is how the company explains price and supply. Aurobindo Pharma Foundation runs the CSR book for underserved communities around plants and beyond. Official X and LinkedIn pages are the public corporate handles. They carry plant news, filings flavour and recruitment, not adverse-event casework. General mail is info@aurobindo.com; investor relations is ir@aurobindo.com on the same contact page. Follow the channels for a 1986 Hyderabad generics house that still presents healthier life as a supply-chain problem, then verify every plant, ANDA and capacity number on aurobindo.com.